Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
SBIL-2	NCIT_C29418	[An retroviral vector encoding human IL-2 with potential antineoplastic property. SBIL-2 (Surgery Branch IL-2) can be used to transfect tumor infiltrating lymphocytes, which can then be re-introduced back to cancer patients, thereby stimulate T cell activation and immunopotentiation responses.]
TP53 NM_000546.5:c.638G>T	NCIT_C146887	[A nucleotide substitution at position 638 of the coding sequence of the TP53 gene where guanine has been mutated to thymine.]
TP53 NP_000537.3:p.R213L	NCIT_C146888	[A change in the amino acid residue at position 213 in the cellular tumor antigen p53 protein where arginine has been replaced by leucine.]
SCAB	NCIT_C29419
BRAF NM_004333.4:c.1801A>G	NCIT_C146880	[A nucleotide substitution at position 1801 of the coding sequence of the BRAF gene where adenine has been mutated to guanine.]
BRAF Exon 15 Mutation	NCIT_C158854	[A molecular genetic abnormality indicating the presence of a mutation in exon 15 of the BRAF gene.]
BRAF NP_004324.2:p.K601E	NCIT_C146881	[A change in the amino acid residue at position 601 in the serine/threonine protein kinase B-raf protein where lysine has been replaced by glutamic acid.]
Tumor Treating Fields Therapy	NCIT_C146882	[A type of electromagnetic field therapy that uses low-intensity, intermediate-frequency alternating electrical fields to a target area to induce selective toxicity to proliferating cells.]
Electric Field Therapy	NCIT_C64860
Mediastinal Granulocytic Sarcoma	NCIT_C146883	[A malignant tumor that arises from the mediastinum and is composed of myeloblasts, neutrophils and neutrophil precursors. It is the most common type of myeloid sarcoma affecting the mediastinum.]
Mediastinal Myeloid Sarcoma	NCIT_C45741	[A mass-forming malignant neoplasm that arises from the mediastinum and is characterized by the proliferation of myeloblasts or immature myeloid cells. It may present in association with or precede acute myeloid leukemia, or it may be the first manifestation of relapse of acute myeloid leukemia.]
Cellular Tumor Antigen p53	NCIT_C17387	[Cellular tumor antigen p53 (393 aa, ~44 kDa) is encoded by the human TP53 gene. This protein plays a role in the regulation of both the cell cycle and apoptosis.]
TP53 Gene	NCIT_C17359	[This gene plays a critical role in cell cycle regulation and has tumor suppressor activity.]
TP53 NM_000546.5:c.524G>A	NCIT_C146885	[A nucleotide substitution at position 524 of the coding sequence of the TP53 gene where guanine has been mutated to adenine.]
TP53 NP_000537.3:p.R175H	NCIT_C146886	[A change in the amino acid residue at position 175 in the cellular tumor antigen p53 protein where arginine has been replaced by histidine.]
Chromosome Arm 3p Loss of Heterozygosity	NCIT_C132246	[A molecular abnormality that results in monoallelic loss of function mutations located within the short arm of chromosome 3 (3p).]
Loss of Heterozygosity	NCIT_C18016	[A genetic variation where gain, loss, or exchange of DNA results in monoallelic loss of function mutations in a diploid cell. In the context of tumor suppressor genes, where a single copy is sufficient for functionality, loss of function for the second allele is associated with tumorigenesis.]
Chromosome Arm 9p Loss of Heterozygosity	NCIT_C132247	[A molecular abnormality that results in monoallelic loss of function mutations located within the short arm of chromosome 9 (9p).]
AJCC v8 Stage	NCIT_C132248	[A cancer stage defined according to the AJCC 8th edition criteria.]
Disease Stage Qualifier	NCIT_C28108